Diagnostic utility of daytime salivary melatonin levels in Smith-Magenis syndrome

American Journal of Medical Genetics, Part A

Volumn 152, Issue 1, 2010, Pages 96-101

  Chik, Constance L ^a   Rollag, Mark D ^b   Duncan, Wallace C ^c   Smith, Ann C M ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Melatonin; Saliva; Smith Magenis syndrome

Indexed keywords

ARIPIPRAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; LAMOTRIGINE; MELATONIN; MELATONIN DERIVATIVE; QUETIAPINE; RETINOIC ACID INDUCIBLE PROTEIN I; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HORMONE DETERMINATION; HUMAN; INFANT; MALE; MOOD DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; SALIVA ANALYSIS; SALIVA LEVEL; SALIVA MELATONIN LEVEL; SCHOOL CHILD; SEIZURE; SLEEP DISORDER; SMITH MAGENIS SYNDROME; AGE; CIRCADIAN RHYTHM; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG USE; GENETIC ANALYSIS; PROTEIN BLOOD LEVEL; SLEEP PATTERN;

ABNORMALITIES, MULTIPLE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MELATONIN; SALIVA; SYNDROME;

EID: 75149146548     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.33158     Document Type: Article

References (32)

1. Boudreau EA, Johnson KP, Jackman A, Blancato J, Huizing M, Bendavid C, Jones M, Chandrasekharappa SC, Lewy AJ, Smith ACM, Magenis E. 2009. Review of disrupted sleep pattern in Smith-Magenis syndrome and normal melatonin secretion in a patient with an atypical interstitial 17p11.2 deletion. Am J Med Genet Part A 149A:1382-1391.
2. Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E, Rollag MD. 2001. Action spectrum for melatonin regulation in humans: Evidence for a novel circadian photoreceptor. J Neurosci 21:6405-6412.
3. Brzezinski A. 1997. Melatonin in humans. N Engl J Med 336:186-195.
4. Buxton OM, Lee CW, L'Hermite-Baleriaux M, Turek FW, Van Cauter E. 2003. Exercise elicits phase shifts and acute alterations of melatonin that vary with circadian phase. Am J Physiol 284:R714-R724.
5. Colley AF, Laversha MA, Voullaire LE, Rogers JG. 1990. Five cases demonstrating the distinctive behavioural features of chromosome deletion 17(p11.2p11.2) (Smith Magenis syndrome). J Pediatr Child Health 26:17-21.
6. Cornelissen G, Halberg F, Tarquini R, Perfetto F, Salti R, Laffi G, Otsuka K. 2003. Point and interval estimations of circadian melatonin ecphasia in Smith-Magenis syndrome. Biomed Pharmacother 57:31s-34s.
7. De Leersynder H, De Blois MC, Claustrat B, Romana S, Albrecht U, Von Kleist-Retzow JC, Delobel B, Viot G, Lyonnet S, Vekemans M, Munnich A. 2001a. Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. J Pediatr 139:111-116.
8. De Leersnyder H, de Blois MC, Vekemans M, Sidi D, Villain E, Kindermans C, Munnich A. 2001b. β1-adrenergic antagonists improve sleep and behavioural disturbance in a circadian disorder, Smith-Magenis syndrome. J Med Genet 38:586-590.
9. Deng DX, Glaze D, Reiter RJ, Tan DX, Lupski JR. 2007. Circadian rhythm abnormalities of mclatonin in Smith-Magenis syndrome patients with RAll mutation. Annual Meeting of the American Society of Human Genetics, Abs No. 636.
10. Duncan W, Morse R, Krasnewich D, Smith A. 2004. Body temperature and sleep disturbance in Smith-Magenis Syndrome. Annual Meeting of the American Society of Human Genetics, Abs No. 814.
11. Greenberg F, Guzzeta V, Montes de Oca-Luna R, Magenis E, Smith AC, Richter SF, Kondo I, Dobyns WB, Patel PI, Lupski JR. 1991. Molecular analysis of the Smith-Magenis syndrome: A possible contiguous-gene syndrome associated with del(17)(p11.2). Am J Med Genet 49: 1207-1218.
12. Greenberg F, Lewis RA, Potocki L, Glaze D, Parke J, Killian J, Murphy MA, Williamson D, Brown E, Dutton R, McCluggage C, Friedman E, Sulek M, Lupski JR. 1996. Multidisciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2). Am J Med Genet 62:247-254.
13. Griefahn B, Bröde P, Remer T, Blaszkewicz M. 2003. Excretion of 6-hydroxymelatonin sulfate (6-OHMS) in siblings during childhood and adolescence. Neuroendocrinology 78:241-243.
14. Kennaway DJ, Voultsios A. 1998. Circadian rhythm of free melatonin in human plasma. J Clin Endocrinol Metab 83:1013-1015.
15. Kennaway DJ, Stamp GE, Goble FC. 1992. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab 75:367-369.
16. Lewy AJ. 2007. Melatonin and human chronobiology. Cold Spring Harb Symp Quant Biol 72:623-636.
17. Lewy AJ, Ahmed S, Jackson JM, Sack RL. 1992. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 9:380-392.
18. Mayeda A, Mannon S, Hofstetter J, Adkins M, Baker R,HuK, Nurnberger J Jr. 1998. Effects of indirect light and propranolol on melatonin levels in normal human subjects. Psychiatry Res 81:9-17.
19. McIntyre IM, Norman TR, Burrows GD, Armstrong SM. 1987. Melatonin rhythm in human plasma and saliva. J Pineal Res 4:177-183. Moore RY, Klein DC. 1974. Visual pathways and the central control of a circadian rhythm in pineal serotonin N-acetyltransferase activity. Brain Res 71:17-33.
20. Nowak R, McMillen JC, Redman J, Short RV. 1987. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: Two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol 27:445-452.
21. Potocki L, Glaze D, Tan DX, Park SS, Kashork CD, Shaffer LG, Reiter RJ, Lupski JR. 2000. Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. J Med Genet 37:428-433.
22. Reiter RJ. 2003. Melatonin: Clinical relevance. Best Pract Res Clin Endocrinol Metab 17:273-285.
23. Rollag MD, Niswender GD. 1976. Radioimmunoassay of serum concentrations of melatonin in sheep exposed to different lighting regimens. Endocrinology 98:482-489.
24. Slager RE, Newton TL, Vlangos CN, Finucane B, Elsea SH. 2003. Mutations in RAI1 associated with Smith-Magenis syndrome. Nat Genet 3:466-468.
25. Smith AC, McGavran L, Robinson J, Waldstein G, Macfarlane J, Zonona J, Reiss J, Lahr M, Allen L, Magenis E. 1986. Interstitial deletion of (17) (p11.2p11.2) in nine patients. Am J Med Genet 24:393-414.
26. Smith AC, Dykens E, Greenberg F. 1998. Sleep disturbance in Smith-Magenis syndrome (del 17p11.2). Am J Med Genet 81:186-191.
27. Smith ACM, Allanson JE, Elsea SH, Finucane BM, Haas-Givler B, Gropman A, Johnson KP, Lupski JR, Magenis E, Potocki L, Solomon B. 2006. Smith-Magenis syndrome. In: GeneReviews at GeneTests. University of Washington, Seattle: Medical Genetics Information Resource (database online). Available at http://www.genetests.org.
28. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Rojdmark S. 2000. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 56:123-127.
29. Waldhauser F, Weiszenbacher G, Frisch H, Zeitlhuber U, Waldhauser M, Wurtman RJ. 1984. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1:362-365.
30. Wolff A, Begleiter A, Moskona D. 1997. A novel system of human submandibular/sublingual saliva collection. J Dent Res 76:1782-1786.
31. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. 2001. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 86:4727-4730.
32. Zisapel N. 2007. Sleep and sleep disturbances: Biological basis and clinical implications. Cell Mol Life Sci 64:1174-1186.